The Disciplinary Record: How Medical Boards Have Responded to Ivermectin Prescribing — and What It Means for Patients
In the United States, the authority to discipline physicians rests not with the federal government but with state medical boards — independent regulatory bodies charged with protecting the public from unprofessional or unsafe medical practice. Over the past several years, these boards have found themselves at the center of a contentious debate: when, if ever, does prescribing ivermectin for off-label indications constitute grounds for professional discipline? The answers have varied considerably by state, and the downstream effects on patient access have been substantial.
The Regulatory Framework: What Medical Boards Can and Cannot Do
State medical boards derive their authority from state medical practice acts — statutes that define the standards of professional conduct required to maintain a medical license. Boards can investigate complaints, impose conditions on licenses, suspend practice privileges, and, in the most serious cases, revoke a physician's license entirely. They operate largely independent of federal drug regulatory policy, which means that a physician can be disciplined for prescribing a federally legal medication if the board determines that the prescribing pattern fell below the applicable standard of care.
This distinction is important: the question before a medical board is not whether ivermectin is legal, but whether a specific physician's prescribing decisions met the professional standard applicable in their state. The standard of care is not a fixed statutory rule — it is a judgment about what a reasonably competent physician in the same specialty and circumstances would have done.
Documented Cases and Patterns of Enforcement
Publicly available records from state medical boards reveal a range of enforcement responses to ivermectin prescribing. In several states, including Oregon, California, and New York, boards issued formal guidance or policy statements indicating that prescribing ivermectin for COVID-19 without credible clinical evidence could constitute unprofessional conduct. These statements were not disciplinary actions themselves, but they served as public signals about the regulatory risk physicians faced.
In other states, formal disciplinary proceedings were initiated against individual physicians. The complaints that prompted these investigations typically shared common characteristics: prescriptions written without an adequate patient examination, dosing that exceeded established antiparasitic guidelines, and, in some cases, prescribing patterns that appeared to prioritize patient demand over clinical judgment. Several cases also involved physicians who operated through telehealth platforms with minimal patient contact, raising questions about whether the prescribing relationship met the legal threshold for a valid physician-patient encounter.
It should be noted that not all investigations resulted in discipline. In a number of cases, boards reviewed complaints and declined to take formal action, finding that the physician's conduct, while perhaps unconventional, did not fall below the applicable standard of care. These outcomes reflect the genuine ambiguity of the regulatory environment and the absence of a uniform national standard.
The Legal Standards Being Applied
For physicians who did face formal discipline, the legal rationale centered on several recurring themes. First, boards cited the absence of adequate documentation — records that failed to demonstrate that the prescribing decision was grounded in a thorough clinical assessment. Second, some boards found that physicians had failed to adequately inform patients about the experimental nature of the proposed treatment and the absence of FDA approval for the relevant indication. Third, in cases involving unusually high doses or combinations with other medications, boards pointed to deviation from established pharmacological guidelines.
What is notable about these standards is that they are, in principle, content-neutral: they apply to the process of prescribing rather than to ivermectin specifically. A physician who documented a thorough examination, obtained informed consent, and prescribed within defensible dosing parameters faced a meaningfully different regulatory risk profile than one who did not. This distinction has been largely absent from public discourse about medical board enforcement, which has often been characterized as ideologically motivated suppression of dissenting clinical opinion.
Divergence Across States: A Patchwork of Risk
One of the most consequential features of the enforcement landscape is its geographic inconsistency. States with historically aggressive medical board enforcement cultures — California, Oregon, and Washington among them — have been more active in pursuing complaints related to ivermectin prescribing. States with more permissive regulatory environments, or those whose legislatures have taken explicit positions favorable to physician autonomy in prescribing decisions, have seen considerably less enforcement activity.
Several states went further, passing or proposing legislation specifically designed to protect physicians from board discipline for ivermectin prescribing. Tennessee, for example, enacted legislation limiting the ability of its medical board to discipline physicians solely on the basis of prescribing FDA-approved medications for off-label uses. Similar proposals were introduced in other states with varying degrees of success. These legislative interventions reflect a broader political contest over the appropriate scope of medical board authority — one that shows no signs of resolution.
The Patient Access Consequence
The chilling effect of medical board enforcement on patient access to ivermectin prescriptions has been documented anecdotally and, to a lesser extent, empirically. Physicians in states with active enforcement environments have reported declining to prescribe ivermectin for off-label indications not because they believe the drug is without merit but because the professional risk is, in their assessment, disproportionate to the clinical benefit they can offer.
For patients in those states, the practical consequence is a narrowing of the legitimate prescribing pool. Physicians willing to write off-label ivermectin prescriptions in high-enforcement states tend to be those operating at the margins of conventional practice — which itself creates a selection effect that may not serve patient interests. Patients who cannot access prescriptions through mainstream channels are more likely to turn to less regulated alternatives, including veterinary formulations, online pharmacies operating outside U.S. jurisdiction, and compounding arrangements of uncertain quality.
What the Record Suggests Going Forward
The disciplinary record on ivermectin prescribing does not tell a simple story of regulatory overreach or of professional negligence. It tells a story of an institution — American medical licensure — struggling to apply standards designed for a more stable evidentiary environment to a situation in which the evidence itself is contested and politically charged.
For patients, the practical takeaway is this: the availability of ivermectin prescriptions through legitimate channels is not uniform across the United States, and that non-uniformity is in significant part a product of the enforcement actions documented here. Understanding the regulatory landscape of one's own state — and the professional pressures facing potential prescribers — is now an unavoidable part of navigating access to this medication.